Emergent nets itself more trouble as it receives a warning letter from the FDA

Emergent BioSolutions is facing a fresh set of manufacturing troubles as the FDA issued a warning to the company regarding its Baltimore site.

Emergent revealed in an SEC filing on Friday that the US regulator issued a warning letter on Aug. 10, flagging two areas of concern at the company’s Camden manufacturing facility in Baltimore.